We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nexalin Lacked Design Control Procedures, FDA Finds
Nexalin Lacked Design Control Procedures, FDA Finds
Missing design control procedures for Nexalin Technology’s transcranial electrotherapy stimulator landed the firm a Form 483 following an inspection of its Houston, Texas facility.
To View This Article:
Login
Subscribe To International Devices & Diagnostics Monitor